We’re excited to announce our new partnership with Y Combinator-backed Atlas Discovery, a startup leveraging the power of AI agents to accelerate biomedical research.
Their system identified an existing FDA-approved drug with the potential to be repurposed to treat CCM, a disease that currently has no cure. Using the tools available through our CureDriver Lab™ and clinical programs— cell lines, mouse colonies, an extensive patient registry and biobank, and 22 Centers of Excellence — we’ll soon begin pre-clinical testing to explore this opportunity.
“We’re excited about the potential of our partnership with Atlas Discovery to dramatically speed up the path to real treatments for our patients,” said Connie Lee, CEO of Alliance to Cure. “By combining their AI technology with our industry-dedicated pre-clinical testing resources, we can move faster than ever before to help people living with this often devastating condition.”
Read more on Atlas’s blog: https://atlasdiscovery.bio/alliance-to-cure-partnership
